Testing added therapy for high-risk neuroblastoma in children
Treatments studied
Part of Cancer clinical trials.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a confirmed diagnosis of neuroblastoma or ganglioneuroblastoma (verified by tumor testing or a bone marrow finding plus urine tumor markers).
- Your child must be between about 1 year old and 30 years old at diagnosis (and meet specific high-risk risk-group details for eligibility).
- Your child should be considered “high-risk” and usually should not have had prior whole-body (systemic) treatment for high-risk disease, except very limited, allowed situations.
- Your child must have adequate organ function, including blood-filtering kidney function and liver enzyme levels within the study limits.
- Your child must have a strong-enough heart pumping function on echocardiogram (ultrasound of the heart).
- If joining the lorlatinib (ALK) portion (Arm E), your child’s tumor must have an ALK alteration, and they must not have previously taken lorlatinib or another ALK inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
Hear when a new Ganglioneuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.